Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Lesinurad

Catalog No: tcsc1389

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
878672-00-5

Formula:
$C_{17}H_{14}BrN_3O_2S$

Pathway:
Membrane Transporter/Ion Channel

Target:
URAT1

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 39 mg/mL (96.47 mM)

Alternative Names:
RDEA594

Observed Molecular Weight:
404.28

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Lesinurad is a **URAT1** and **OAT** inhibitor, is determined to be a substrate for the kidney transporters **OAT1** and **OAT3** with $\mathbf{K_m}$ values of 0.85 and 2 μM, respectively.

IC50 & Target: Km: 0.85 μM (OAT1), 2 μM (OAT3)[1]

In Vitro: Lesinurad is a novel selective uric acid reabsorption inhibitor (SURI). Lesinurad is determined to be a substrate for the kidney transporters organic anion transporter (OAT1) and OAT3 with K_m values of 0.85 and 2 μM, respectively[1]. Lesinurad (RDEA594) is a URAT1 and OAT inhibitor, which increases proximal renal tubule urate excretion[2]. Lesinurad (RDEA594) is a potential uric acid lowering agent througn inhibition of uric acid reuptake, and exhibits favorable p450 profiles, inhibits CYP2C9 and CYP2C8 with IC_{50} of 14.4 μM and 16.2 μM, respectively. IC_{50}s of Lesinurad are all above 100 μM for CYP1A2, CYP2C19,and CYP2D6[3].

In Vivo: Lesinurad (RDEA594) shows better pharmacokinetics than its pro-drug RDEA806. The 100 mg dose of Lesinurad exhibits a phamacological effect in the range of that produced by 300 mg to 800 mg single doses of RDEA806[3].